ReviewInternational journal of molecular sciences2022
Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the evolution and research landscape of ferroptosis-targeted nanomedicine: insights from a scientometric analysis.Frontiers in pharmacology · 2024Pooled it
- The Translational Paradox of Cancer Nanomedicine: Biological, Pharmacokinetic, and Manufacturing Barriers to Clinical Success.Biology · 2026Review
- Artificial Intelligence-Driven Nanomedicine: From Drug Formulation and Nanocarrier Design to Clinical Translation.Pharmaceutics · 2026Review
- BBB-aware stimuli-responsive and biomimetic nanomedicines for glioblastoma.Chinese neurosurgical journal · 2026Review
- From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics.Asian journal of pharmaceutical sciences · 2026Review
- Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025Review
- Comparison of therapeutic potential of macrophage- or mesenchymal stem cell-derived exosomes in pancreatic cancer: An updated review.World journal of stem cells · 2025Review
- Engineered Sustainable Mxene-PVA Hydrogel as an Inspiring Co-Delivery Carrier for Targeting Solid Tumors.Pharmaceutics · 2025Article
- Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery.Molecular cancer · 2025Review
- Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Recent advances in self-targeting natural product-based nanomedicines.Journal of nanobiotechnology · 2025Review
- A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer.Drug delivery and translational research · 2025Review
- Nanomedicine: The new trend and future of precision medicine for inflammatory bowel disease.Chinese medical journal · 2024Review
- Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials.Pharmaceutics · 2024Review
- Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer.Journal of personalized medicine · 2024Review
- Swelling, Rupture and Endosomal Escape of Biological Nanoparticles Per Se and Those Fused with Liposomes in Acidic Environment.Pharmaceutics · 2024Article
- Synthesis of Submicron CaCOMicromachines · 2024Article
- The Role of Nanomedicine in Benign Gynecologic Disorders.Molecules (Basel, Switzerland) · 2024Review
- Ultrasound-activated prodrug-loaded liposome for efficient cancer targeting therapy without chemotherapy-induced side effects.Journal of nanobiotechnology · 2024Article
- Evaluation of biogenically synthesized MgO NPs anticancer activity against breast cancer cells.Saudi journal of biological sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The ultimate goal of nanomedicine has always been the generation of translational technologies that can ameliorate current therapies. Cancer disease represented the primary target of nanotechnology applied to medicine, since its clinical management is characterized by very toxic therapeutics. In this effort, nanomedicine showed the potential to improve the targeting of different drugs by improving their pharmacokinetics properties and to provide the means to generate new concept of treatments based on physical treatments and biologics. In this review, we considered different platforms that reached the clinical trial investigation, providing an objective analysis about their physical and chemical properties and the working mechanism at the basis of their tumoritr opic properties. With this review, we aim to help other scientists in the field in conceiving their delivering platforms for clinical translation by providing solid examples of technologies that eventually were tested and sometimes approved for human therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.